Literature DB >> 10624417

1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

R D Feldman1, N Campbell, P Larochelle, P Bolli, E D Burgess, S G Carruthers, J S Floras, R B Haynes, G Honos, F H Leenen, L A Leiter, A G Logan, M G Myers, J D Spence, K B Zarnke.   

Abstract

OBJECTIVE: To provide updated, evidence-based recommendations for health care professionals on the management of hypertension in adults. OPTIONS: For patients with hypertension, there are both lifestyle options and pharmacological therapy options that may control blood pressure. For those patients who are using pharmacological therapy, a range of antihypertensive drugs is available. The choice of a specific antihypertensive drug is dependent upon the severity of the hypertension and the presence of other cardiovascular risk factors and concurrent diseases. OUTCOMES: The health outcomes considered were changes in blood pressure and in morbidity and mortality rates. Because of insufficient evidence, no economic outcomes were considered. EVIDENCE: MEDLINE searches were conducted from the period of the last revision of the Canadian Recommendations for the Management of Hypertension (January 1993 to May 1998). Reference lists were scanned, experts were polled and the personal files of the authors were used to identify other studies. All relevant articles were reviewed, classified according to study design and graded according to levels of evidence. VALUES: A high value was placed on the avoidance of cardiovascular morbidity and premature death caused by untreated hypertension. BENEFITS: Harms and costs: The diagnosis and treatment of hypertension with pharmacological therapy will reduce the blood pressure of patients with sustained hypertension. In certain settings, and for specific drugs, blood pressure lowering has been associated with reduced cardiovascular morbidity and mortality. RECOMMENDATIONS: This document contains detailed recommendations pertaining to all aspects of the diagnosis and pharmacological therapy of hypertensive patients. With respect to diagnosis, the recommendations endorse the greater use of non-office-based measures of blood pressure control (i.e., using home blood pressure and automatic ambulatory blood pressure monitoring equipment) and greater emphasis on the identification of other cardiovascular risk factors, both in the assessment of prognosis in hypertension and in the choice of therapy. On the treatment side, lower targets for blood pressure control are advocated for some subgroups of hypertensive patients, in particular, those with diabetes and renal disease. Implicit in the recommendations for therapy is the principle that for the vast majority of hypertensive patients treated pharmacologically, practitioners should not follow a stepped-care approach. Instead, therapy should be individualized, based on consideration of concurrent diseases, both cardiovascular and noncardiovascular. VALIDATION: All recommendations were graded according to the strength of the evidence and the consensus of all relevant stakeholders. SPONSORS: The Canadian Hypertension Society and the Canadian Coalition for High Blood Pressure Prevention and Control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624417      PMCID: PMC1253506     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  130 in total

1.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

2.  Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel.

Authors:  T Pickering
Journal:  Am J Hypertens       Date:  1996-01       Impact factor: 2.689

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 4.  Atherosclerosis and urate metabolism.

Authors:  B T Emmerson
Journal:  Aust N Z J Med       Date:  1979-08

5.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

6.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  Self-recording of blood pressure in the management of hypertension.

Authors:  A L Johnson; D W Taylor; D L Sackett; C W Dunnett; A G Shimizu
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

8.  Difficulties in diagnosing hypertension: implications and alternatives.

Authors:  H M Perry; J P Miller
Journal:  J Hypertens       Date:  1992-08       Impact factor: 4.844

9.  The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial.

Authors:  L L Van de Ven; J T Van Leeuwen; A J Smit
Journal:  Vasa       Date:  1994       Impact factor: 1.961

10.  Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function.

Authors:  J S Gottdiener; S V Livengood; P S Meyer; G A Chase
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

View more
  39 in total

1.  Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.

Authors:  B H Chen
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

2.  Beta-blockers as first-line therapy for hypertension.

Authors:  G A Heckman; A Papaioannou; W Parkinson; C A Patterson
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

3.  New Canadian hypertension recommendations. So what?

Authors:  N R Campbell
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

Review 4.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Health outcomes associated with calcium antagonists.

Authors:  R B Thakkar; S Oparil
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

6.  2000 Canadian hypertension recommendations. Summary of recommendations affecting family physicians.

Authors: 
Journal:  Can Fam Physician       Date:  2001-04       Impact factor: 3.275

7.  Slowing the progression of chronic renal insufficiency.

Authors:  Marcello Tonelli; John Gill; Sanjaya Pandeya; Clara Bohm; Adeera Levin; Bryce A Kiberd
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

8.  Hypertension and alpha-adrenergic blockers: preliminary ALLHAT results.

Authors:  B H Chen
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

Review 9.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease.

Authors:  Caroline Stigant; Lesley Stevens; Adeera Levin
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

10.  Markers of loss of control of hypertension.

Authors:  Richard Ian Casson; Will D King; Noah Marshall S Godwin
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.